Abstract Library

#3863 Survival and prognostic factors in appendiceal neuroendocrine tumors (ANET) and goblet cell carcinoma (aGCC)

Introduction: Appendiceal goblet cell carcinomas (aGCC) present with overlapping features of appendiceal neuroendocrine neoplasms (ANET) and adenocarcinomas. A previous study found that ANET with peritoneal metastases have a 5-year survival rate of 7%. Recent studies show that ANET rarely metastasizes, contrary to aGCC. The latest WHO classification excluded aGCC from the group of NETs and classified it as appendiceal adenocarcinomas.

Conference:

Presenting Author: Dijke K

Authors: Dijke K, Levy S, van den Berg J, Tesselaar M,

Keywords: Goblet cell carcinoma, Appendiceal neuroendocrine tumor, Survival,

#3480 Is addition of NETest to clinical parameters valuable in the prognostication of patients with Small Intestinal Neuroendocrine Tumors (SI-NET)?

Introduction: A previously established nomogram based on clinical parameters was associated with disease specific survival (DSS) in patients with SI-NET, yet it underestimated DSS. (1,2)

Conference:

Presenting Author: Levy S

Authors: Levy S, van Treijen M, Tesselaar M, Valk G,

Keywords: SI-NET, Nomogram, NETest, DSS, PFS,

#3475 Serum Activin A is not associated with carcinoid heart disease (CHD) in patients with neuroendocrine tumors (NET)

Introduction: CHD is a fibrotic cardiac disorder that is caused by serotonin secreted by NET, especially in the presence of liver metastases. Currently, N terminal pro B type natriuretic peptide (NT-proBNP) is used to detect cardiac damage due to CHD, yet no predictive biomarkers are available. Activin A has been identified as a potential biomarker for CHD.

Conference:

Presenting Author: Levy S

Authors: Levy S, Kilgallen A, Korse C, Oerlemans M, Sluijter J,

Keywords: CHD, carcinoid heart disease, biomarker, NT-proBNP, Activin A,

#3465 Opposite treatment approach in two institutes identifies primary tumor resection to be associated with improved disease specific mortality in patients with stage IV small intestinal neuroendocrine tumors (SI-NET) vs watch-and-wait strategy

Introduction: SI-NET often present with metastatic disease. There is an ongoing debate whether or not to perform primary tumor resection (PTR) in stage IV SI-NET.

Conference:

Presenting Author: Levy S

Authors: Levy S, Arthur J, Banks M, Kok N, Fenwick S,

Keywords: SI-NET, surgical approach, stage 4, instrumental variable,

#3280 A patient derived organoid model of neuroendocrine neoplasms enables long-term growth in vitro of low grade tumors and reveals therapeutic vulnerabilities

Introduction: A paucity of in vitro and in vivo models has limited the study of neuroendocrine neoplasms (NENs).

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Dayton T

Authors: Dayton T, Alcala N, Den Hartigh L, Moonen L, Levy S,

Keywords: organoids, growth factor dependencies, lung NETs,